Virtus Fund Advisers’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Virtus Fund Advisers’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$348K	Buy	+4,411	New	+$326K	﹤0.01%	410

Other funds holding MLNT

Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Virtus Fund Advisers's MLNT Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2017: 4,411 shares worth $348K. The stake represents ﹤0.01% of the portfolio and ranks #410 among its holdings.

78 funds tracked by Wall St. Rank hold MLNT as of Q4 2017.

Virtus Fund Advisers held 4,411 shares of Melinta Therapeutics, Inc. Common Stock worth $348K as of Q4 2017.
Melinta Therapeutics, Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
Melinta Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #410 holding.
78 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.